Non-Opioid Pain Drug Cuts Knee Surgery Prescriptions

In a retrospective review, knee replacement patients given Journavx were more likely to leave the hospital without an opioid prescription.

Updated on Nov. 7, 2026 in Arthritis

Photo-style view of a single white capsule on an empty stainless steel tray beside a folded blue surgical drape in a bright clinical room.
Patients given the non-opioid pain drug Journavx after knee replacement were more likely to leave the hospital without an opioid prescription, a retrospective study presented at the American Association of Hip and Knee Surgeons Annual Meeting found. AI Illustration. Upload story photo >

A retrospective study presented at the American Association of Hip and Knee Surgeons Annual Meeting found that patients who received Journavx (suzetrigine), a non-opioid pain medication made by Vertex, after total knee replacement were more likely to be discharged without an opioid prescription. The findings are most relevant to adults undergoing knee replacement and the surgeons and care teams who manage their post-operative pain.

Why it matters

Opioid prescriptions after joint replacement are common, and reducing them is a central goal of post-surgical pain management because of dependence and misuse risks. The study adds early real-world data on how a non-opioid option may fit into standard post-surgical care, though it compares groups rather than proving cause and effect.

This retrospective review compared 106 primary unilateral total knee replacement patients who received Journavx alongside standard post-operative pain care against 1,487 patients who received standard care alone. Researchers adjusted for age, gender and BMI and stratified results by inpatient versus outpatient procedures, but the study design cannot establish that Journavx itself caused the differences observed.

The players

Vertex

Vertex is a biotechnology company known for its cystic fibrosis therapies and its development of suzetrigine, a non-opioid pain treatment.

American Association of Hip and Knee Surgeons

The American Association of Hip and Knee Surgeons is a professional medical society representing orthopedic surgeons who perform hip and knee joint replacement procedures.

The details

Journavx is suzetrigine, a non-opioid pain medication that works by blocking a specific sodium channel involved in transmitting pain signals rather than acting on opioid receptors in the brain. In this study, it was used as part of multimodal pain management, meaning it was combined with other standard post-operative medications. Researchers compared whether patients received Journavx or standard care alone, and tracked prescription fills and refills over 30 days. Mean morphine milligram equivalents were consistently lower in the Journavx group, indicating less total opioid exposure.

Timeline

  1. The study was reported with results published by Healio on November 7, 2026.

  2. Opioid prescription fills and refills were tracked over a 30-day follow-up period after surgery.

Health Landscape

Journavx is a newer class of pain reliever that acts on a different pathway than opioids, entering a market dominated for decades by opioid-based post-surgical prescribing. This study adds to a growing body of evidence on opioid-sparing strategies after joint replacement, a procedure performed in very large numbers across the United States each year.

If you are preparing for knee replacement, it is worth asking your surgeon whether a non-opioid pain plan is part of their post-operative approach and how it may affect your prescription needs. Discuss any questions about pain management options with your physician, since individual suitability depends on your health history.

The takeaway

Opioid-sparing pain plans are an active area of surgical care, and patients are encouraged to raise pain management preferences with their surgical team before a procedure. Ask your physician how post-operative pain will be managed and whether a non-opioid option is appropriate for you.

Further reading

For broader context on joint conditions and their treatment, explore our Arthritis coverage.

Source note: This article includes information reported by Healio.